Halozyme Therapeutics (HALO) FY2020 results: revenue $268 million, up 36.5% on the year
Halozyme Therapeutics, Inc. (HALO) reported revenue of $268 million for fiscal 2020, the year ended 31 December 2020, up 36.5% on the year before. Net income was $129 million, and diluted earnings per share $0.91. The figures are the company's own, from the 10-K it filed with the SEC on 23 February 2021.
Revenue
$268 million
+36.5% on the year
FY2013FY2020
Operating margin
53.9%
-34.5% a year earlier
FY2013FY2020
Net income
$129 million
FY2013FY2020
Diluted EPS
$0.91
FY2013FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
268
196
152
+36.5%
Cost of revenue
43.4
45.5
10.1
-4.8%
Gross profit
224
150
142
+49.0%
Gross margin
83.8%
76.8%
93.3%
Research and development
34.2
141
150
-75.7%
Selling, general and administrative
45.7
77.3
60.8
-40.8%
Operating income
144
-67.6
-69.3
Operating margin
53.9%
-34.5%
-45.7%
Interest expense
20.4
11.6
18.0
+75.3%
Pre-tax income
129
-72.3
-79.8
Income tax
0.2
-0.0
0.5
Effective tax rate
0.2%
n/a
n/a
Net income
129
-72.2
-80.3
Net margin
48.2%
-36.9%
-52.9%
Diluted EPS
$0.91
-$0.50
-$0.56
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
55.5
-85.4
-49.5
Capital expenditure
2.5
4.0
4.7
-38.0%
Free cash flow
53.0
-89.5
-54.2
Free cash flow margin
19.8%
-45.6%
-35.7%
Cash from investing
78.4
-5.5
2.5
Cash from financing
-106
153
-63.8
Depreciation and amortisation
3.3
4.1
2.4
-19.3%
Share-based compensation
17.2
34.8
35.7
-50.5%
Buybacks
150
200
0.0
-24.9%
Diluted shares, weighted
141m
144m
144m
-2.0%
Shares outstanding at period end
135m
137m
143m
-1.2%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
151
91.8
249
+64.6%
Debt
397
403
126
-1.3%
Other liabilities
31.6
71.5
65.0
-55.7%
Total liabilities and equity
580
566
440
+2.5%
Fixed assets
7.3
10.9
7.5
-32.8%
Investments
220
301
297
-26.8%
Cash and equivalents
148
120
57.9
+22.9%
Receivables
97.7
59.4
30.0
+64.4%
Inventory
60.7
29.4
22.6
+106.9%
Other assets
46.1
45.0
25.6
+2.6%
Total assets
580
566
440
+2.5%
10-K for the year ended 31 December 2020, filed 23 February 2021: the filing.